NPI: 1922724707 · BOULDER, CO 80305 · Family Medicine Physician · NPI assigned 10/13/2022
Authorized official GIBSON, SABRINA controls 20+ related entities in our dataset. Read more
| Authorized Official | GIBSON, SABRINA (CFO) |
| NPI Enumeration Date | 10/13/2022 |
Other providers sharing the same authorized official: GIBSON, SABRINA
| Provider | City | State | Total Paid |
|---|---|---|---|
| ROCKY MOUNTAIN CLINICS LLC | FORT COLLINS | CO | $9.63M |
| ROCKY MOUNTAIN CLINICS LLC | PUEBLO | CO | $307K |
| ROCKY MOUNTAIN CLINICS LLC | GREELEY | CO | $159K |
| ROCKY MOUNTAIN CLINICS LLC | COLORADO SPRINGS | CO | $156K |
| ROCKY MOUNTAIN CLINICS LLC | LONGMONT | CO | $137K |
| ROCKY MOUNTAIN CLINICS LLC | AURORA | CO | $101K |
| ROCKY MOUNTAIN CLINICS LLC | NORTHGLENN | CO | $94K |
| ROCKY MOUNTAIN CLINICS LLC | LOVELAND | CO | $67K |
| ROCKY MOUNTAIN CLINICS LLC | ENGLEWOOD | CO | $57K |
| ROCKY MOUNTAIN CLINICS LLC | STEAMBOAT SPRINGS | CO | $26K |
| ROCKY MOUNTAIN CLINICS LLC | GRAND JUNCTION | CO | $24K |
| ROCKY MOUNTAIN CLINICS LLC | WALSENBURG | CO | $22K |
| ROCKY MOUNTAIN CLINICS LLC | STERLING | CO | $22K |
| ROCKY MOUNTAIN CLINICS LLC | FORT COLLINS | CO | $20K |
| ROCKY MOUNTAIN CLINICS LLC | COMMERCE CITY | CO | $8K |
| ROCKY MOUNTAIN CLINICS, LLC | ESPANOLA | NM | $4K |
| ROCKY MOUNTAIN CLINICS LLC | WELLINGTON | CO | $3K |
| ROCKY MOUNTAIN CLINICS LLC | DURANGO | CO | $2K |
| ROCKY MOUNTAIN CLINICS LLC | PUEBLO | CO | $1K |
| ROCKY MOUNTAIN CLINICS, LLC | TAOS | NM | $0.00 |
| Year | Claims | Total Paid |
|---|---|---|
| 2022 | 53 | $3K |
| 2023 | 730 | $39K |
| 2024 | 133 | $6K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 445 | 318 | $42K |
| 80305 | 404 | 297 | $5K | |
| 81025 | 22 | 17 | $163.59 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 14 | 14 | $160.60 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 17 | 16 | $0.00 |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | 14 | 14 | $0.00 |